abstract |
The purpose of the present invention is to provide a novel method for treating human T-lymphotropic virus 1-associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers (ACs) and a remedy therefor, said method and remedy being different from the conventional remedies. A method for treating HAM patients and ACs, said method being characterized by comprising decreasing HTLV-1 virus-infected cells using an anti-human CC-chemokine receptor 4 (CCR4) antibody, and a remedy therefor. |